Method and composition for treating or preventing a respiratory illness. The method includes administering at least one dose of a pharmaceutically acceptable fluid having a pH less than 3.0 into contact with at least one region of the respiratory tract present in a patient in need thereof. Respiratory illness that can be treated include COVID-19.

There is provided a skin-care balm comprising 15% to 45% (w/w) of two or more waxes, wherein a first wax has a melting point of 70° C. to 90° C. and a second wax has a melting point of 30° C. to 60° C., the balm further comprising 45% to 70% (w/w) of an emollient and a skin soothing agent. The skin-care balm can be applied to the skin in the perinasal area. There is also provided a combination product comprising a skin-care balm and a nasal spray product.

There is provided a skin-care balm comprising 15% to 45% (w/w) of two or more waxes, wherein a first wax has a melting point of 70° C. to 90° C. and a second wax has a melting point of 30° C. to 60° C., the balm further comprising 45% to 70% (w/w) of an emollient and a skin soothing agent. The skin-care balm can be applied to the skin in the perinasal area. There is also provided a combination product comprising a skin-care balm and a nasal spray product.

A combination product comprising a dispensing head (10, 10′) mounted on a top of a container (20, 20′) containing a formulation for nasal administration, and a solidified skin-care balm (50) for application around the nose contained in a balm holder element (30, 30″) located on a bottom (24) of the container (20).

A combination product comprising a dispensing head (10, 10′) mounted on a top of a container (20, 20′) containing a formulation for nasal administration, and a solidified skin-care balm (50) for application around the nose contained in a balm holder element (30, 30″) located on a bottom (24) of the container (20).

An inhaler (10) for the inhalation of inhalable substances comprise: a canister (50) having an interior reservoir (84) containing pressurised inhalable substances including fluid; a metering valve (52) including a metering chamber (82) and a valve stem (54) defining a communication path between the metering chamber and the interior reservoir, the communication path (86) including an opening (106) configured to permit flow between a transfer space inside the valve stem and the interior reservoir, the interior reservoir being arranged for orientation above the metering chamber whereby gas such as air located within the metering chamber is replaced with liquid from the interior reservoir.

An inhaler (10) for the inhalation of inhalable substances comprise: a canister (50) having an interior reservoir (84) containing pressurised inhalable substances including fluid; a metering valve (52) including a metering chamber (82) and a valve stem (54) defining a communication path between the metering chamber and the interior reservoir, the communication path (86) including an opening (106) configured to permit flow between a transfer space inside the valve stem and the interior reservoir, the interior reservoir being arranged for orientation above the metering chamber whereby gas such as air located within the metering chamber is replaced with liquid from the interior reservoir.

The present embodiments provide compositions, methods and kits for the treatment of ocular conditions or maladies affecting the back of the eye, e.g., the retina.

The present embodiments provide compositions, methods and kits for the treatment of ocular conditions or maladies affecting the back of the eye, e.g., the retina.

A solid matrix sustained release ophthalmic formulation for topical delivery of a solid ophthalmic drug to the eye, medical devices, drug cores, drug inserts and drug delivery systems comprising the formulation, methods of manufacturing the formulation, medical devices and their methods thereof for delivering the ophthalmic drug for a treatment period provided herein. The formulation disclosed herein is an admixture of an ophthalmic drug, and a combination of a hydrophobic polymer, a hydrophilic polymer and a surfactant, wherein the drug is eluted daily over an extended period of time at therapeutic dose of drug.